NEO

NeoGenomics($NEO) Top Executives and Board Make $555,000 Cluster Buy Following Stock Plunge

05/13/2025 20:13

Senior executives and board members of NeoGenomics Inc ($NEO), a U.S. cancer diagnostics service provider, have initiated substantial stock purchases following a recent steep decline in share price. This cluster buying, involving seven insiders over a two-week period beginning in early May, signals strong management confidence in the company's value. NEO's stock price plummeted after disappointing financial results. On April 29, the company reported Q1 2025 revenue of $168.04 million, a 7.5% year-over-year increase but below the market expectation of $170.96 million. This news triggered a one-day 34% drop in share price to the $6 range, representing more than a 60% decline from the $16 level seen in July last year. The insider buying began immediately after this price collapse, with CFO Jeffrey Sherman purchasing 20,000 shares at $7.51 (approximately $150,000) on May 2. This was followed by Director David Perez acquiring 10,000 shares at $7.63 (about $76,300) on May 5, and Director Neil Gunn buying 4,510 shares at $7.75 (roughly $35,000) on the same day. CEO Anthony Zook joined the buying spree on May 6, purchasing 18,900 shares at $7.88 (about $149,000). Director Stephen Kanovsky acquired 4,000 shares at $7.78 (approximately $31,000) on May 7, while Director Lynn Tetrault bought 7,000 shares at $8.14 (about $57,000) on May 9. The cluster buying concluded with COO Warren Stone purchasing 5,700 shares at $8.58 (approximately $49,000) on May 12. In total, seven insiders acquired 70,110 shares worth approximately $555,000. NeoGenomics operates as a comprehensive clinical laboratory specializing in cancer diagnostic testing services. The company utilizes diverse diagnostic technologies in pathology, genomics, and molecular biology to provide precision diagnostic services for cancer patients. The cancer diagnostics market is expected to grow with trends toward precision medicine and personalized treatment approaches. CEO Anthony Zook is a pharmaceutical industry veteran who joined NeoGenomics in February 2023 after serving as global head of commercial operations at AstraZeneca. CFO Jeffrey Sherman came aboard in August 2022, previously serving as CFO at Inovalon Holdings. COO Warren Stone joined in April 2023 and has been working to improve operational efficiency. Notably, these insider transactions were voluntary decisions rather than automatic trades under any 10b5-1 plan. The participation of the entire C-suite (CEO, CFO, COO) along with multiple board members suggests strong internal confidence in the company's future prospects. In contrast, during 2024, executive Alicia C. Olivo conducted two small sales: 1,040 shares at $16.05 (about $17,000) on August 15 and 5,175 shares at $15.36 (approximately $79,000) on November 15. However, these transactions were related to performance stock units and can be viewed separately from long-term company outlook. In its February 2025 earnings report, $NEO provided annual revenue guidance of $735-745 million for 2025, exceeding analysts' expectations of $727.70 million. However, the first quarter revenue shortfall has raised concerns about achieving this full-year target. Currently, 10 of 15 analysts maintain a 'buy' or stronger recommendation for $NEO, with the remaining five suggesting 'hold.' There are no 'sell' ratings. The median price target stands at $17.50, implying more than 100% upside potential from current levels. The cancer diagnostics services market is anticipated to see continued growth driven by an aging population, increasing cancer incidence rates, and advances in precision medicine. However, NeoGenomics faces challenges from intensifying competition and rising costs. The company is pursuing strategies to improve efficiency and expand high-margin testing services to enhance profitability. This substantial buying by management may indicate that the stock is undervalued and demonstrates internal conviction in the company's long-term potential. Nevertheless, investors should consider the possibility of continued volatility until performance improvements materialize. The upcoming Q2 2025 earnings report and any updates to annual guidance will likely serve as important catalysts for determining stock direction.

You can receive notifications when news is published.